Jason Duncan - 11 Dec 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Chief Legal Officer
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Jason Duncan
Issuer symbol
NMRA
Transactions as of
11 Dec 2023
Net transactions value
$0
Form type
4
Filing time
12 Dec 2023, 18:16:39 UTC
Previous filing
02 Mar 2023
Next filing
18 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Award $0 +400,000 $0.000000 400,000 11 Dec 2023 Common Stock 400,000 $12.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.